Lava Therapeutics B.V (LVTX)

Etorro trading 970x250

About Lava Therapeutics B.V

Address: Yalelaan 60, Utrecht, Netherlands, 3584 CM

Lava Therapeutics B.V News and around…

Latest news about Lava Therapeutics B.V (LVTX) common stock and company :

40 Biggest Movers From Friday
03 Jan, 2022 FinancialContent

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean ...

CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20 Dec, 2021 Yahoo! Finance

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph should be Wednesday, Jan. 12, 2022 at 1:30 p.m. EST instead of Wednesday, Jan. 12, 2021 at 1:30 p.m. EST. Completed corrected text follows. LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T

LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20 Dec, 2021 Yahoo! Finance

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2021 at 1:30 p.m. EST. “We

Oversold Conditions For LAVA Therapeutics
14 Dec, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
15 Nov, 2021 Yahoo! Finance

LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on track to begin enrolling later this quarterLAVA-051 granted orphan drug designation by the U.S. FDA for the treatment of CLLCash and investments of $142 million as of Sept. 30, 2021 UTRECHT, The Netherlands and PHILADELPHIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clin

Q&A: CEO Stephen Hurly explains why Lava Therapeutics chose Philadelphia over Boston
11 Nov, 2021 Yahoo! Finance

Hurly talks about the company's decision to go public, its post-IPO growth, and why it set up shop here.

LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
11 Nov, 2021 Yahoo! Finance

The Antibody Society Logo Logo for The Antibody Society UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that LAVA and The Antibody Society, a non-profit association, are co-organizing a virtual symposium Emerging cancer therapies leveraging gamma-delta effector T cells taking place on Mon., Nov. 29, 2021 from 11 a.m. to 2 p.m. EST / 17.00 to 20.00 CET.

LAVA Therapeutics Expands Management Team with Three Key Appointments
09 Nov, 2021 Yahoo! Finance

Jessica Truscello, vice president, clinical operations, LAVA Therapeutics Jessica Truscello appointed vice president of clinical operations at LAVA Therapeutics Sumeet Ambarkhane, M.D., executive medical director, LAVA Therapeutics Sumeet Ambarkhane, M.D. appointed as an executive medical director at LAVA Therapeutics. Wouter van Hunnik, vice president, head of human resources, LAVA Therapeutics Wouter van Hunnik appointed vice president, head of human resources at LAVA Therapeutics. UTRECHT, Th

LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
04 Nov, 2021 Yahoo! Finance

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer at LAVA, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference taking place

LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
02 Nov, 2021 Yahoo! Finance

Paul W.H.I. Parren, Ph.D., EVP, Head of R&D to share data regarding LAVA bispecific gamma delta T cell engagers derived from proprietary Gammabody™ platformUTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Paul W.H.I. Parren, P

The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
15 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of ...

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
15 Oct, 2021 Yahoo! Finance

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia (CLL). CLL is a form of leukemia characterized by progressive accumulation of abnormal lymphocytes in the peripheral blood, bone mar

35 Biggest Movers From Friday
11 Oct, 2021 FinancialContent

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s ...

CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 Oct, 2021 Yahoo! Finance

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in the second paragraph Vγ9Vδ2 T cells were incorrectly written as V9V2 T cells. The corrected release follows: LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today an

LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 Oct, 2021 Yahoo! Finance

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Hans van der Vliet, M.D,. Ph.D., chief scientific officer at LAVA, will present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021. “Gamm

Could The Lava Therapeutics B.V. (NASDAQ:LVTX) Ownership Structure Tell Us Something Useful?
23 Sep, 2021 Yahoo! Finance

A look at the shareholders of Lava Therapeutics B.V. ( NASDAQ:LVTX ) can tell us which group is most powerful...

60 Biggest Movers From Friday
13 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported ...

Forbion Appoints Nanna Lüneborg as a General Partner
01 Sep, 2021 FinancialContent
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
16 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

88 Biggest Movers From Yesterday
05 Aug, 2021 FinancialContent

Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from ...

Oversold Conditions For LAVA Therapeutics (LVTX)
04 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

75 Biggest Movers From Yesterday
04 Aug, 2021 FinancialContent

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company ...

48 Stocks Moving In Tuesday's Mid-Day Session
03 Aug, 2021 FinancialContent

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed ...

21 Stocks Moving in Tuesday's Pre-Market Session
03 Aug, 2021 FinancialContent

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 46% to $6.35 in pre-market trading following Form 4 filing from ...

61 Biggest Movers From Yesterday
03 Aug, 2021 FinancialContent

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company ...

40 Stocks Moving In Monday's Mid-Day Session
02 Aug, 2021 FinancialContent

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million ...

21 Stocks Moving in Monday's Pre-Market Session
02 Aug, 2021 FinancialContent

Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 41.5% to $1.91 in pre-market trading. Ipsen and Exicure signed an exclusive ...

LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
27 Jul, 2021 FinancialContent
75 Biggest Movers From Friday
26 Jul, 2021 FinancialContent

Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired ...

Lava Therapeutics B.V (LVTX) is a NASDAQ Common Stock listed in

970x250